Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-28
2009-10-06
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S049000
Reexamination Certificate
active
07598240
ABSTRACT:
A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1):(wherein n is 3 or 4; R represents ethyl or hydrogen; and R1represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are an intermediate for the compound and a process for producing the compound.
REFERENCES:
patent: 3873555 (1975-03-01), Bowden
patent: 3910904 (1975-10-01), Worley
patent: 3923709 (1975-12-01), Worley
patent: 4584300 (1986-04-01), Iwao et al.
patent: 4755509 (1988-07-01), Teulon
patent: 4771050 (1988-09-01), Meguro et al.
patent: 5496817 (1996-03-01), Kawashima et al.
patent: 6713477 (2004-03-01), Scarlato et al.
patent: 2004/0043984 (2004-03-01), O'Brien
patent: 2005/0282905 (2005-12-01), Horiuchi
patent: 10-84987 (1998-04-01), None
patent: 10-120621 (1998-05-01), None
patent: 2000-309575 (2000-11-01), None
patent: 2002-37761 (2002-02-01), None
patent: 2002-128769 (2002-05-01), None
patent: 2002-542238 (2002-12-01), None
patent: WO 96/20936 (1996-07-01), None
patent: WO 03/055851 (2003-07-01), None
patent: WO 2004/014389 (2004-02-01), None
Masanobu Fujita, et al., “A Novel, Convenient Synthesis of 2-Aryl-3-oxo-3,4-dihydro-2H-1,4-benzothiazines”,Synthesis, Aug. 1988, pp. 599-604.
J.W. Worley, et al., “2-Dialkylphosphonyl- and 2-Alkylidene-3,4-dihydro-3-oxo-2H-1,4-benzothiazines”,J. Org. Chem., vol. 40, No. 12, 1975, pp. 1731-1734.
Hiroyuki Tawada, et al., “Studies on Antidiabetic Agents. IX. A New Aldose Reductase Inhibitor, AD-5467, and Related 1-4-Benzoxazine and 1-4-Benzothiazine Derivatives: Synthesis and Biological Activity”,Chem. Pharm. Bull., vol. 38, No. 5, 1990, pp. 1238-1245.
Giuseppe Trapani, et al., “Synthesis of 2-Substituted-N-Carboxymethyl-1,5-Benzothiazepin-4-Ones and—1,4-Benzothiazin-3-Ones and their Evaluation as Angiotensin Converting Enzyme Inhibitors”,Il Farmaco, vol. 50, No. 2, 1995, pp. 107-112.
Masahiro Kajino, et al., “Synthesis and Biological Activities of New 1,4-Benzothiazine Derivatives”,Chem. Pharm. Bull., vol. 39, No. 11, 1991, pp. 2888-2895.
Sarah E. Kelly and Thomas G. LaCour, “An Efficient Synthesis of (S)-2-Hexylthiodecanoic Acid”,Tetrahedron: Asymmetry, vol. 3, No. 6, 1992, pp. 715-718.
Zhe Wang, et al., “Enantioselective Synthesis of α-Hydroxy Carboxylic Acids: Direct Conversion of α-Oxocarboxylic Acids to Enantiomerically Enriched α-Hydroxy Carboxylic Acids via Neighboring Group Control”,Tetrahedron Letters, vol. 39, 1998, p. 5501-5504.
Yasuo Yoshihara, et al., “Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoic arthritis or osteoarthritis”,Annals of the Rheumatic Diseases, vol. 59, No. 6, 2000, pp. 455-461.
R. Clark Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”,J. Clinical Investigation, vol. 99, No. 7, 1997, pp. 1534-1545.
Yuichi Nagakawa, et al., “Histologic Features of Venous Invasion, Expression of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9, and the Relation with Liver Metastasis in Pancreatic Cancer”,Pancreas, vol. 24, No. 2, 2002, pp. 169-178.
Francesco Sinigaglia and Juergen Hammer, “Motifs and Supermotifs for MHC Class II Binding Peptides”,J. Exp. Med., vol. 181, Feb. 1995, pp. 449-451.
E.M. O'Byrne, et al., “Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits”,Inflamm. Res., vol. 44, Supplement 2, 1995, pp. S117-S118.
A. Yamada, et al., “ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs”,Inflamm. Res., vol. 49, 2000, pp. 144-146.
E.J. Lewis, et al., “Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo”,British Journal of Pharmacology, vol. 121, 1997, pp. 540-546.
Alexander Rosemurgy, et al., “Marimastat in Patients With Advanced Pancreatic Cancer”,Am. J. Clin. Oncol. (CCT), vol. 22, No. 3, 1999, pp. 247-252.
M. J. Janusz, et al., “Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor”,Osteoarthritis and Cartilage, vol. 10, 2002, pp. 785-791.
Fukuda Nobuhisa
Horiuchi Yoshihiro
Makita Atsushi
Samizo Fumio
Tsuboi Katsunori
Dainippon Sumitomo Pharma Co. ,Ltd.
Habte Kahsay T
Sughrue & Mion, PLLC
LandOfFree
Benzothiazin-3-one compound and intermediate therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzothiazin-3-one compound and intermediate therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiazin-3-one compound and intermediate therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134726